



Curriculum Vitae Andrew S. Kraft, MD

Academic Positions

- 2005 - Present Associate Dean for Oncology Affairs, Medical University of South Carolina
- 2005 - Present Professor of Biochemistry and Molecular Biology, Medical University of South Carolina
- 2004 - Present Director, Hollings Cancer Center, William H. Folk, MD Chair in Experimental Oncology, Professor of Medicine, Medical University of South Carolina, Charleston, South Carolina
- 1996 - 2004 Professor of Medicine, Chief, Division of Medical Oncology, The Stapp/Harlow Professor of Cancer Research, University of Colorado Health Sciences Center, Denver, CO
- 1997 - 2004 Professor, School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, CO
- 1996 - 2004 Head, Sarcoma Program, University of Colorado Cancer Center
- 1996 - 2004 Head, Experimental Therapeutics Program, University of Colorado Cancer Center
- 1994 - 1996 Associate Director, Division of Hematology/Oncology University of Alabama at Birmingham
- 
2.27.09
- 1992 - 1996 Professor of Medicine, Division of Hematology/Oncology Associate Professor of Biochemistry-Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham
- 1987 - 1992 Associate Professor of Medicine, Division of Hematology/Oncology, Associate Professor of Biochemistry-Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham

1983 - 1987 Assistant Professor of Medicine, Division of Hematology/Oncology,
Assistant Professor of Biochemistry-Associate Scientist, Comprehensive
Cancer Center, University of Alabama at Birmingham

Education

1971 B.S., Biology, (Summa Cum Laude) Bucknell University, Lewisburg, PA
1971-1975 M.D., University of Pennsylvania, Philadelphia, PA
1975-1976 Medical Internship, The Mount Sinai Hospital, New York, NY
1976-1978 Residency Internal Medicine, The Mount Sinai Hospital, New York, NY
1978-1979 Emergency Room Physician, Sibley Hospital Washington, DC, and The
Alexandria Hospital, Alexandria, VA
1979-1982 Research Associate, Laboratory of Pathophysiology, National Cancer
Institute, National Institutes of Health, Bethesda, MD
1982-1983 Clinical Staff Fellow, National Cancer Institute, National Institutes of
Health, Bethesda, MD

Board Certification

1980 Internal Medicine
1985 Oncology

Honors

1989 Fogarty Fellow, Chester Beatty Laboratory, London, United Kingdom
1989 Haddow Fellow, Chester Beatty Laboratory, London, United Kingdom
1995 CaPCure Award
1996 French ARC Fellowship
1997 Monfort Professor of Cancer Research
2003 Yamagiwa-Yoshida UICC International Grant
2006 Pfizer Visiting Professorship in Oncology – Texas Tech University, Health
Sciences Center

Elected Professional Society Memberships

American Society for Clinical Investigation
Association of American Physicians

Additional Professional Societies

American Association of Cancer Research
Southern Society of Clinical Investigations
Western Association of Physicians
American Society of Hematology
Charleston County Medical Society
American Society of Biologic Chemists

Reviewer of Scientific Journals for:

Biochemical Pharmacology
Blood
Cancer Research

International Journal of Cancer
Molecular Biology of the Cell
Molecular and Cellular Biology

Proceedings of the National Academy of Sciences

Editorial Boards

Cancer Biology

Cancer Biology & Molecular Therapy

Medical University of South Carolina Duties:

Committee Chair to Recruit Division Chief of Hematology/Oncology

Clinical Research Task Force

Backfill Space Committee

Drug Discovery Building Steering Committee

Bioengineering/Life Sciences Building Steering Committee

South Carolina Cancer Disparities Community Network Steering Committee

Clinical and Translational Science Award Internal Planning Committee

Chair of Surgery Search Committee

Chair of Search Committee for Oncology Service Line Director

Clinical Enterprise Strategic Plan Steering Committee

University of Colorado Cancer Center Duties

Head, Experimental Therapeutics Program

Space Committee Member

Member - Breast Cancer Program Director Recruitment Committee

Clinical Cancer Center Director Recruitment Committee

Clinical Cancer Center Committee

University of Colorado Health Sciences Committees

Backfill Space Committee

Recruitment Committee to select a Head for Medical Genetics

Committee to formulate a development plan for Ph.D.s in the Department of Medicine

School of Medicine Research Retreat Committee to formulate 5-year University Plan

National Committees

NIH Study Section - Ad Hoc Member Hematology Study Section

Southwest Oncology Group – Sarcoma and Genitourinary Committee

ASCO Program Committee

NCI-Cancer Center Site Visit Committee

University of Chicago November 2007

University of Miami February 2008

Patent Pending

Kraft AS and Smith CH
INHIBITORS OF Pim-1 PROTEIN KINASE, COMPOSITIONS, AND METHODS FOR
TREATING PROSTATE CANCER

Vortex Biotechnology Corporation (Start-up company)
Andrew S. Kraft, MD, President and Chief Medical Officer

Invited Lectures

- 1988 Biologic Response Modifier Branch, National Cancer Institute, Fred., MD
- 1989 Shering Research Corporation, Bloomfield, New Jersey
- 1990 Chemistry and Biology of Bryostatin 1, National Cancer Institute, Frederick, MD
- 1992 Meeting on Oncogenes, Hood College, Frederick, MD
- 1992 Department of Microbiology, University of Kansas Medical Center, Kansas City, Kansas
- 1992 Department of Microbiology, Eastern Virginia Medical School, Norfolk, VA
- 1993 Department of Pharmacology, University of Wisconsin, Madison, WI
- 1995 Division of Oncology, Univ. of Colorado, Denver, CO.
- 1996 CaPCure Prostate Cancer Retreat
- 1996 International Workshop on “Cytokines, signaling and the JAK/STAT pathway”
- 1997 Grand Rounds - Department of Medicine University of Colorado Health Sciences Center
- 1997 Department of Chemistry - University of Colorado Boulder
- 1998 School of Pharmacy - University of Colorado Health Sciences Center
- 2000 Division of Hematology/Oncology- Children’s Hospital, Denver CO
- 2000 Division of Medical Oncology – University of Pittsburg, Pittsburgh, PA
- 2000 Cancer Center – Mt. Sinai Medical School, New York, NY
- 2001 Cancer Center – University of Rochester, Rochester, NY
- 2002 Walter and Eliza Hall Institute, Melbourne, Australia
- 2003 H. Lee Moffitt Cancer Center and Research Institute
- 2003 University of Massachusetts Medical Center, Worcester, Mass.
- 2004 Amgen, Thousand Oaks, California
- 2004 Human Genome Sciences, Rockville, Maryland
- 2004 University of Kentucky, Lexington, Kentucky
- 2004 Exelixis, South San Francisco, CA
- 2004 Wake Forest University, Winston-Salem, NC
- 2005 TGen – Translational Genomics Research Institute, Phoenix, AZ
- 2005 South Carolina Oncology Society, Charleston, SC
- 2006 Winship Cancer Center, Emory University, Atlanta, GA
- 2006 Piedmont Oncology Association Program Committee, Charleston, SC
- 2006 University of South Carolina, Columbia, SC
- 2007 Texas Tech University, Lubbock, TX
- 2008 Charles University in Prague, Czech Republic

Current Funding

Granting Agency – National Institutes of Health / National Cancer Institute **1P30 CA138313-01**

Title: Medicinal University of South Carolina Cancer Center Support Grant

Principal Investigator – Andrew S. Kraft, MD Total Project Period 7/1/09 – 6/30/14

Total Funding - \$7,830,976

Granting Agency – Department of Defense

Title: The Mechanism of Action of Unique Small Molecules that Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth

Principal Investigator – Andrew S. Kraft, MD Total Project Period 4/1/09-3/31/2012

Total Funding - \$375,000 Total Funding

Granting Agency – Avon Corporation

Title: HCC Breast Cancer Patient Navigation

Principle Investigator – Andrew S. Kraft

Total Funding \$250,000

Granting Agency – State of South Carolina

Title: Center of Economic Excellence in Tobacco Related Malignancy

Principle Investigator – Andrew S. Kraft

Total Funding \$5,000,000

Granting Agency – State of South Carolina

Title: Center of Economic Excellence in Gastrointestinal Malignancy

Co-investigator – Andrew S. Kraft

Total Funding \$5,000,000

Granting Agency – State of South Carolina

Title: Center of Economic Excellence in Stem Cell Biology & Therapy

Co-investigator – Andrew S. Kraft

Total Funding \$5,000,000

Pending Funding

Granting Agency – National Institute of Health

Title: Inhibiting Pim Protein Kinase as Leukemia Therapy

Principal Investigator – Andrew S. Kraft, M.D. Total Project Period 12/1/09-11/30/09

Total Funding - \$1,843,750 Total Direct & Indirect Costs for Entire Project Period

Granting Agency – National Institutes of Health STTR 1 R41 CA135804-01A2

Title: Novel Inhibitors of Pim Protein Kinases

Principal Investigator – Andrew S. Kraft, MD Total Project Period 7/1/09-6/30/10

Total Funding \$250,000

Recent Past Funding

Granting Agency – American Cancer Society BC-522, BC-522A

Title: The Mechanism of Action of Phorbol Ester

Principal Investigator – Andrew S. Kraft, M.D.

Total Funding - \$292,800 Total Project Period 1/1/86 – 12/31/90

Granting Agency – Department of the Navy N00014-89-006

Title: Therapeutic Use of Bryostatin 1 in Bone Marrow Failure and Over-Whelming Sepsis

Principal Investigator - Andrew S. Kraft, M.D.

Total Funding – \$400,848 Total Project Period 3/15/89 – 3/14/92

Granting Agency – Fogarty International Center F06 tw01522-01

Title: The Role of Protein Kinase C in Mediating N-RAS Protein Transcriptional Activation

Principal Investigator – Andrew S. Kraft, M.D.

Total Funding – \$19,200 Total Project Period 8/1/89 – 7/31/90

Granting Agency - American Cancer Society RPG-93-019-06-CDD

Title: Preclinical Studies of the Anticancer Agent Bryostatin

Principal Investigator - Andrew S. Kraft, M.D.

% Effort - 10%

Total Project Period 7/1/93 - 6/30/99

Granting Agency – Council for Tobacco Research 3749R2

Title: Regulation of mRNA Transcription by Jun Family Members

Principal Investigator – Andrew S. Kraft, M.D.

Total Funding – \$109,608 Total Project Period 1/1/94 – 7/31/96

Granting Agency - National Institutes of Health R03CA66634

Title: Bryostatin Therapy in Chronic Myelogenous Leukemia

Principal Investigator - Andrew S. Kraft, MD

Total Funding - \$100,000 Total Project Period- 4/1/95 - 3/31/97

Granting Agency - National Institutes of Health R21CA68284

Title: Bryostatin 1 Therapy of Metastatic Melanoma

Principal Investigator - Andrew S. Kraft, M.D.

Total Project Period - 9/15/95 - 8/31/98

Granting Agency - CaPCure

Title: Bryostatin-1 based therapy of prostate cancer

Principal Investigator - Andrew S. Kraft, MD

Total Project Period - 1/23/97-1/27/98

Granting Agency - Department of Defense

Title: Chemotherapy of Late Stage Breast Cancer targeted Towards Cell Cycle Regulatory Components.

Principal Investigator - Dr. Tom Langan

% Effort - 10%

Total Project Period - 10/1/98-9/30/02

Granting Agency - National Institutes of Health DK 44741

Title: The Mechanism of Action of GM-CSF

Principal Investigator - Andrew S. Kraft, MD

Total Project Period 10/1/95 - 10/30/02

Granting Agency - National Institutes of Health CA78631

Title: Regulation of Prostate Cancer Programmed Cell Death

Principal Investigator - Andrew S. Kraft, MD

Total Funding - \$620,140 Total Project Period - 8/14/98 - 04/30/02

Granting Agency - National Institutes of Health -Training grant, T32 CA79446-05

Title: Clinical Pharmacology of Antineoplastic Agents

Principal Investigator - Andrew S. Kraft, MD

Total Funding \$778,261 Total Project Period 9/1/99 - 8/31/04

Granting Agency - Department of Defense, DAMD 17-01-1-0045

Title: Overcoming Resistance of Prostate Cancer to TRAIL-Mediated Apoptosis

Principal Investigator - Andrew S. Kraft, MD

Total Funding \$620,000 Total Project Period – 06/01/01-06/30/04

Granting Agency – Prostate Cancer Foundation (CaPCure)

Title: Pim protein kinase – levels correlate with human prostate cancer growth – prevents chemotherapy killing: investigations into Pim mechanism of action.

Principal Investigator – Andrew S. Kraft, MD

Total Funding \$75,000 Total Project Period 1/31/04 – 1/30/05

Granting Agency - National Cancer Institute, 7R21 CA95183-03

Title: Pim-1 Protein Kinase As A Target for Drug Discovery

Principal Investigator - Andrew S. Kraft, MD

Total Funding \$200,000 Total Project Period 4/1/02-3/31/06 1-year no cost extension

Granting Agency – National Cancer Institute (NCI) 5P20 CA093282-03

Title: Hollings Cancer Center Planning Grant

Principal Investigator – Andrew S. Kraft, M.D.

Total Funding \$350,044 Total Project Period 08/24/04 – 07/31/06

Granting Agency – Department of Defense, DAMD, W81XWH 05-1-0126

Title: Pim Protein Kinase – Levels correlate with Prostate Tumor growth and chemotherapy resistance – potential Mechanism of Pim Action

Principal Investigator – Andrew S. Kraft, M.D.

Total Funding \$375,000

Total Project Period 12/1/04 -11/30/07 no cost extension

Granting Agency-National Institutes of Health, 5R01 CA104710-05

Title: Mechanisms by Which Proteasome Inhibitors Enhance Apoptosis

Principal Investigator - Andrew S. Kraft, M.D.

Total Funding \$1,000,000

Total Project Period 03/01/03-02/29/08

No cost extension through 02/29/09

Post-Doctoral Fellows

Past

James Reeves - 1985-88
Marie Wooten - 1986-87
Felicia William - 1986-89
Tino Unlap - 1989-92
Christopher Franklin - 1989-94
Samuel Adunyah - 1989-92
Victor Adler - 1991-94
Clement Asiedu - 1993-96
Ikuya Sakai - 1993-96
William Jackson - 1995-96
Tetsuya Matsuguchi - 1995-96
Srikanth Sampathkumar - 1996-1998
John Pawlowski – 1997 –2000
Linsheng Zhang-2000
Masaoki Takano-2000
Sookhee Bang-2000

Tammie Yeh-2000-2001
Yuri Ionov – 1999-2001
Alexander Nesterov - 1998-2002
Joseph Biggs – 1994-2004
Tim Johnson – 1997-2004
Malti Nikrad -2001-2004
Wei Wei Chen-2002-2006
Youhang Zhang -2002-2006
Changmin Chen – 2005-2006
Julianna Soosirajah – 2004-2005
Sean Xiong – graduate student 2004-2007
Jian Ma – 2004 -2007
Suiquan Wang – 2004-2007
Karthikeyan Kandasamy – 2005-2008
Fengxue Zhang – 2007-2008

Current

Sandeep Mahajan - 2005
Jin Song – 2006
Zanna Beharry - 2007
Bo Cen - 2008
Marina Zemskova – 2008
Yin Wei Lin - 2008

Clinical Protocols

| <u>Hollings Cancer Center Principal Investigator</u> | | | |
|---|---------------------|-----------------------|-----------------------------|
| <u>Protocol Title</u> | <u>Phase</u> | <u>Sponsor</u> | <u>Total Funding</u> |
| Phase I Trial of Concurrent Taxotere with Radiation Therapy and Hormonal Therapy for Clinically Localized High Risk Prostate Cancer | Phase I | MUSC | \$100,000 |
| VELCADE (bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer | Phase II | Millennium | \$164,809 |
| A Phase II Study of Neo-adjuvant Cisplatin, Gemcitabine, & Avastin, followed by Radical Cystectomy for Patients with Muscle Invasive, Resectable, Non-Metastatic Transitional Cell carcinoma (TCC) of the Bladder | Phase II | Genentech, Inc. | \$77,313 |
| A Multicenter, Open-Label, Single-Arm Study of YONDELIS (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment | Phase III | Johnson & Johnson | \$5,000 |
| Phase II Study of Neoadjuvant Gemcitabine/Oxaliplatin and Cetuximab Followed by Surgery or Concurrent External Beam Radiation With Capecitabine for Patients With Locally Advanced Unresectable Nonmetastatic Pancreatic Cancer | Phase II | MUSC | \$102,947 |
| Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer | Phase II | SWOG | \$16,000 |

| | | | |
|--|------------|-----------------------------|-----------|
| A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-tissue or Bone Sarcomas | Phase III | ARIAD Pharmaceuticals, Inc. | \$117,000 |
| ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study) A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ERBB2 Positive Primary Breast Cancer | Phase III | CTSU/NCICCTG | \$18,000 |
| Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer. | Phase III | SWOG | \$16,000 |
| Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer | Phase III | Sanofi-Aventis | \$129,750 |
| A Phase 1/2 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma | Phase I/II | University of Chicago | \$25,000 |
| Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Locally Advanced and Metastatic Bladder Cancer | Phase II | Pfizer | \$40,600 |
| Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. | Phase II | SWOG | \$6,000 |

| | | | |
|---|-----------|--------------------|-----------|
| A Phase I Study of Topotecan in Combination with Vinorelbine in Recurrent Lung Cancer | Phase I | GlaxoSmithKline | \$106,500 |
| Phase I Trial of Bortezomib (VELCADE TM) and Celecoxib in Patients with Advanced Solid Tumors | Phase I | Millennium | \$179,080 |
| Adjuvant Androgen Deprivation Vs Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III | Phase III | SWOG | \$2,000 |
| An Open-Label Study of Capecitabine and Docetaxel as Neoadjuvant Treatment for Patients with Recently Diagnosed HER2-neu Negative Breast Cancer Plus Trastuzumab for HER2-neu Positive Breast Cancer (Xena Trial) | Phase IV | Roche Laboratories | \$51,705 |
| A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) | Phase III | Novacea | \$48,300 |
| A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older with Node Positive or Node-Negative Breast Cancer | Phase III | CTSU/CALGB | \$2,000 |
| A Phase 2 Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC) | Phase II | Johnson & Johnson | \$8,575 |

| | | | |
|---|-----------|-------------------------------|-----------|
| Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients | N/A | NCI | \$4,000 |
| A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination with Carboplatin and Paclitaxel as First Line Therapy in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) | Phase II | Human Genomics Sciences, Inc. | \$13,949 |
| A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer | Phase III | GlaxoSmithKline | \$136,226 |
| A Phase II Trial Of Dasatinib(Sprycel®) In Subjects With Hormonerefractory Prostate Cancer, Previously Treated With Chemotherapy | Phase II | University of CA-Irvine | \$30,000 |

Hollings Cancer Center Co-Investigator

| <u>Protocol Title</u> | <u>Phase</u> | <u>Sponsor</u> | <u>Total Funding</u> |
|--|---------------------|-----------------------|-----------------------------|
| A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib Vs Sorafenib Vs Placebo in Patients with Resected Renal Cell Carcinoma | Phase III | CTSU/ECOG | \$20,000 |
| A Phase I/II Trial Of A Combination Of Paclitaxel And Trastuzumab With Daily Irradiation Or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery For Non -Cystectomy Candidates With Muscle-Invasive Bladder Cancer | Phase I/II | RTOG | \$8,000 |

| | | | |
|--|-------------------|-------------------------|-----------|
| A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer | Phase III | GlaxoSmithKline | \$85,731 |
| A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-tissue or Bone Sarcomas | Phase III | Ariad Pharmaceutical | \$117,000 |
| A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy | Phase III | RTOG | \$12,000 |
| Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma | Pilot/Feasibility | MUSC | \$74,055 |
| A Randomized, Phase III Trial of ABI-007 and Carboplatin® Compared with Taxol® and Carboplatin® as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | Phase III | Abraxis | \$219,650 |
| A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients with Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | Phase II | Abraxis | \$198,700 |
| A Phase II, Open Label, Single Arm Study of AS1411 in Patients with Advanced Renal Cell Carcinoma | Phase II | Abraxis | \$80,753 |

| | | | |
|--|-----------|-----------------|-----------|
| Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressive Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced. Stage IIIb / IV Non-Small Cell Lung Cancer | Phase III | CTSU/CALGB | \$12,000 |
| Postoperative Evaluation of 5-FU by Bolus Injection Vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT Vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT i | Phase III | CALGB | \$8,000 |
| Phase II Study of PEG-Interferon, GM-CSF and Thalidomide in Metastatic Renal Cell Carcinoma | Phase II | Schering-Plough | \$30,000 |
| An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer receiving Letrozole as Adjuvant Therapy | Phase III | Novartis | \$11,781 |
| Phase II Study of Gemcitabine and Cpt-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma. | Phase II | Eli Lilly | \$102,500 |
| Randomized Phase III Study of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC | Phase III | SWOG | \$6,000 |
| A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer | Phase II | SWOG | \$2,000 |

| | | | |
|---|------------|--------------------|-----------|
| Phase I Trial of Bortezomib (PS-341; NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms | Phase I | NCI | \$6,000 |
| A Phase II Randomized Trial for Patients with Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery and Bid Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine | Phase II | RTOG | \$2,000 |
| XELOX - A - DVS (Dense Vs Standard): A Randomized Study of Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q3W) and Bevacizumab versus Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Therapy | Phase II | Roche Laboratories | \$13,708 |
| Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients with Cancers Expressing HER-2 and/or CEA | Phase I | Merck | \$52,459 |
| Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates | Phase II | SWOG | \$2,000 |
| A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer | Phase II | SWOG | \$2,000 |
| A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) | Phase I/II | ZymoGenetics | \$197,320 |

in Subjects with Metastatic Renal Cell
Carcinoma

| | | | |
|--|-----------|-----------------|-----------|
| A Randomized, Double Blinded, Multi-Center Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo as First Line Therapy for Subjects with Metastatic Clear Cell Carcinoma of the Kidney | Phase II | Amgen, Inc. | \$536,176 |
| AXITINIB (AG-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial | Phase III | Pfizer | \$47,500 |
| A Study Pazopanib Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma | Phase III | GlaxoSmithKline | \$121,783 |
| A Phase I Safety and Tolerability Study of LBH589 in Combination with Sorafenib in Patients with Advanced Renal Cell Carcinoma and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies | Phase I | MUSC | \$988,581 |
| A Randomized Double Blind Phase II Trial of Cisplatin plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113 | Phase II | Astra Zeneca | \$18,375 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Advanced or Metastatic (Stage IIIB/IV) NSCLC | Phase III | Novartis | \$52,975 |

Reviews, Editorials and Book Chapters

1. **Kraft AS:** So What's New with Jun? *Am. Journ. of Med Sci.* 302: 176-180, 1991.
2. Woodgett JR, Pulverer BJ, Nikolakaki E, Plyte S, Hughes K, Franklin CC, and **Kraft AS:** Regulation of jun/AP-1 oncoproteins by protein phosphorylation. *Advances in Second Messenger & Phosphoprotein Research.* 28: 261-9, 1993.
3. **Kraft AS:** Bryostatin 1- Will the oceans provide a cancer cure? *J National Cancer Institute;*85: 1790-1792, 1993.
4. Franklin CC, Adler V, and **Kraft AS:** Phosphorylation of transcription factors. *Methods in Enzymology.* Vol: 254, 550-564, 1995.
5. Biggs JR, **Kraft AS:** Inhibitors of Cyclin-dependent Kinase and Cancer. *Journal of Molecular Medicine* 73: 509-514, 1995.
6. Pawlowski, J. and **Kraft, AS.** Bax-induced apoptotic cell death. *Commentary Proc. Natl. Acad. Sci. USA.* 96: 14476-14481, 1999.
7. Nesterov A, **Kraft AS.** In Response 04-4319. *Letter to the Editor Can Res* 2005; 65:(4).

Publications

1. **Kraft AS**, Anderson WB, Cooper HL and Sando JJ: Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatment of EL4 thymoma cells. *J Biol Chem* 257:13193-13196, 1982.
2. Anderson WB, **Kraft AS** and Evain-Brion D: Effect of retinoic acid and phorbol ester treatment of embryonal carcinoma cells on calcium, phospholipid-dependent protein kinase activity. In: Teratocarcinoma Stem Cells, Vol 10 Cold Spring Harbor, 1983.
3. **Kraft AS** and Anderson WB: Phorbol esters increase the amount of calcium phospholipid-dependent protein kinase associated with plasma membrane. *Nature* 301:621-623, 1983.
4. **Kraft AS** and Anderson WB: Characterization of cytosolic calcium-activated phospholipid-dependent protein kinase activity in embryonal carcinoma cells: Effect of retinoic acid-induced differentiation of F9 cells to parietal endoderm. *J Biol Chem* 258:9178-9183, 1983.
5. Berkow RL and **Kraft AS**: Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. *Biochem Biophys Res Comm* 131:1109-1116, 1985.
6. **Kraft AS**: Effect of phorbol esters on the activity of purified transforming growth factors. *Cancer Res* 46:1764-1767, 1986.
7. **Kraft AS**, Smith JB and Berkow RL: Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemic cells HL-60. *Proc Natl Acad Sci USA* 83:1334-1338, 1986.
8. **Kraft AS** and Zuckerman KS: Production of multilineage hemopoietic growth-stimulating activities by a human melanoma cell line. *Exp Hematol* 14:867-872, 1986.
9. Berkow RL, Dodson RW and **Kraft AS**: The effect of a protein kinase C inhibitor, H-7, human neutrophil oxidative burst and degranulation. *J Leuk Biol* 14:441-446, 1987.
10. Berkow RL, Dodson RW and **Kraft AS**: Dissociation of human neutrophil activation events by prolonged treatment with Amiloride. *J Lab Clin Med* 110:97-105, 1987.
11. **Kraft AS** and Berkow RL: Tyrosine kinase and phosphotyrosine phosphatase activity in human promyelocytic leukemia cells and human polymorphonuclear leukocytes. *Blood* 70:356-362, 1987.
12. **Kraft AS**, Baker VV and May WS: Bryostatin induces changes in protein kinase C location and activity without altering *c-myc* gene expression in human promyelocytic leukemia cells (HL-60). *Oncogene* 1:111-118, 1987.
13. **Kraft AS**, Appling C and Berkow RL: Specific binding of phorbol esters to nuclei of human promyelocytic leukemia cells. *BBRC* 144:393-401, 1987.
14. May WS, Sharkis SJ, Esa AH, Gebbia V, **Kraft AS**, Pettit RG and Sensenbrenner LL: Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. *Proc Natl Acad Sci USA* 84:8483-8487, 1987.
15. Lilly MB and **Kraft AS**: Leukemia-differentiating activity expressed by the human melanoma cell lines LD-1. *Leukemia Res* 12:217-225, 1988.
16. **Kraft AS**, Reeves J and Ashendel C: Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells. *J Biol Chem* 263:8437-8442, 1988.
17. William F, Moczowski B, Cohen S and **Kraft AS**: Differentiation of HL-60 cells is associated with an increase in the 35 kDa protein (lipocortin 1). *J Cell Physiol* 137:402-410, 1988.
18. **Kraft AS**, William F, Pettit GR and Lilly M: Varied differentiation responses of human leukemias to Bryostatin 1. *Cancer Res* 49:1287-1293, 1989.

19. William F, Haigler HT and **Kraft AS**: Lack of phosphorylation of lipocortin 1 in A431 epidermoid carcinoma cells treated with phorbol esters. *BBRC* 160:474-479, 1989.
20. Berkow RL, Dodson Robert and **Kraft AS**: Human neutrophils contain distinct cytosolic and particulate tyrosine kinase activities: possible role in neutrophil activation. *Biochem Biophys Acta* 997:292-301, 1989.
21. Fields A, Pincus SM, **Kraft AS** and May WS: Interleukin-3 and Bryostatin 1 mediate rapid nuclear envelope protein phosphorylation in growth factor dependent FDC-P1 hematopoietic cells: *J Biol Chem* 264:21896-21901, 1989.
22. Fields P, Tyler G, **Kraft AS**, and May WS: Role of nuclear protein kinase C in the mitogenic response to platelet derived growth factor. *J Cell Science* 96:107-114, 1990.
23. **Kraft AS**, Wagner F and Housey GM: Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1. *Oncogene* 5:1243-1246, 1990.
24. Lilly MB, Tompkins C, Brown C, Pettit GR and **Kraft AS**: Differentiation and growth modulation of chronic myelogenous leukemia cells by Bryostatin 1. *Cancer Res* 50:5520-5525, 1990.
25. William F, Wagner F, Karin M and **Kraft AS**: Multiple doses of diacylglycerol and calcium ionophore are necessary to activate AP-1 enhancer activity and induce markers of macrophage differentiation. *J Biol Chem* 265:18166-18171, 1990.
26. Naftlin AJ, Gillian GK, Eldridge CS and **Kraft AS**: Induction of the Proto-Oncogene c-Jun by angiotensin II. *Mol Cell Biol* 10:5536-5540, 1990.
27. **Kraft AS** and Ashworth A: Cloning of a potentially soluble receptor for human GM-CSF *Nucleic Acids Res* 18:7178, 1990.
28. Tilden A and **Kraft AS**: The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity. *J Immunother* 10:96-104, 1991.
29. Lilly M, Brown C, Pettit G and **Kraft AS**: Bryostatin 1: A potential anti-leukemic agent of chronic myelomonocytic leukemia. *Leukemia* 5:283-287, 1991.
30. Adunyah SE, Unlap T, Wagner F and **Kraft AS**: Regulation of *c-jun* expression and AP-1 enhancer activity by granulocyte-macrophage colony-stimulating factor. *J Biol Chem* 266:5670-5675, 1991.
31. **Kraft AS**, Wang SS, Xiang J, Pouncey L and Kidd VJ: Regulation of the p58 GTA cell division control-related protein kinase during phorbol 12-myristate 13-acetate-induced terminal differentiation of U937 cells. *Oncogene* 7:501-506, 1992.
32. Adunyah SE, Unlap TM, Franklin CC and **Kraft AS**: Induction of differentiation and c-Jun expression in human leukemic cells by okadaic acid, an inhibitor of protein phosphatases. *J Cell Physiol* 151:415-426, 1992.
33. Franklin CC and **Kraft AS**: Protein kinase C-independent activation of c-jun and c-fos transcription by epidermal growth factor. *Biochem Biophys Acta* 1134:137-142, 1992.
34. Unlap T, Franklin CC, Wagner F and **Kraft AS**: Upstream regions of the c-jun promoter regulate phorbol ester-induced transcription in U937 leukemia cells. *Nucleic Acids Res* 20 4:897-902, 1992.
35. **Kraft AS**, Adler V, Hall P, Pettit G, Benjamin WH and Briles DE: *In vivo* administration of Bryostatin 1, a protein kinase C activator, decreases murine resistance to *Salmonella typhimurium*. *Cancer Res* 52:2143-2147, 1992.

36. Franklin CC, Sanchez V, Wagner F, Woodgett JR and **Kraft AS**: Phorbol ester-induced amino-terminal phosphorylation of human Jun but not Jun B regulates transcriptional activation. *Proc Nat Acad Sci* 89:7247-7251, 1992.
37. Adler V, Franklin CC and **Kraft AS**: Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: Regulation by N-terminal d domain. *Proc Nat Acad Sci* 89:5341-5345, 1992.
38. Adler V, Polotskaya A, Wagner F and **Kraft AS**: Affinity purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. *J Biol Chem* 267:17001-17005, 1992.
39. Pettit GR, Sengupta D, Blumberg PM, Lewin NE, Schmidt JM and **Kraft AS**: Structural modifications of bryostatin 2. *Anti-Cancer Drug Design* 7:101-113, 1992.
40. Pulverer BJ, Hughes K, Franklin CC, **Kraft AS**, Leever SJ and Woodgett JR: Co-purification of mitogen-activated protein kinases with phorbol ester-induced c-jun kinase activity in U937 leukemic cells. *Oncogene* 8:407-415, 1993.
41. Franklin CC, Unlap T, Adler V and **Kraft AS**: Multiple signal transduction pathways mediate c-Jun protein phosphorylation. *Cell Growth & Differentiation* 4:377-385, 1993.
42. Polotskaya A, Zhao Y, Lilly MB and **Kraft AS**: A critical role for the cytoplasmic domain of the granulocyte-macrophage colony-stimulating factor alpha receptor in mediating cell growth. *Cell Growth & Differentiation* 4:423-531, 1993.
43. Berkow RL, Schlabach L, Dodson R, Benjamin WH Jr., Pettit GR, Rustagi PK and **Kraft AS**: In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. *Cancer Res* 53:2810-2815, 1993.
44. Dolan LR, Rutberg SE, Amin S, Emura M, Mohr U, **Kraft AS**, Yokoyama K and Ronai Z: Regulation of c-Jun by lung carcinogens in Clara cells of hamsters. *Carcinogenesis* 15:2789-2793, 1994.
45. Polotskaya A, Zhao Y, Lilly ML and **Kraft AS**: Mapping the intracytoplasmic regions of the α granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. *J Biol Chem* 269:14607-14613, 1994.
46. Adler V, Unlap T and **Kraft AS**: A peptide encoding the c-jun delta domain inhibits the activity of a c-jun amino terminal protein kinase. *J Biol Chem* 269:11186-11191, 1994.
47. Frank SJ, Gilliland G, **Kraft AS** and Arnold CS: Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. *Endocrinology* 135:2228-2239, 1994.
48. Franklin CC, McCulloch V and **Kraft AS**: *In Vitro* association between the Jun protein family and the general transcription factors, TBP and TFIIB. *Biochem J* 305:967-974, 1995.
49. Adler V and **Kraft AS**: Regulation of AP-3 enhancer activity during hematopoietic differentiation. *J Cell Physiol* 164:26-34, 1995.
50. Dai T, Rubie E, Franklin CC, **Kraft AS**, Gillespie DAF, Avruch J, Kyriakis J and Woodgett JR: Stress-activated protein kinases bind directly to the d domain of c-Jun in resting cells: implications for repression of c-Jun function. *Oncogene* 101:849-855, 1995.
51. Zhao Y, Wagner F, Frank SJ and **Kraft AS**: The amino terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor bc chain. *J Biol Chem* 270:13814-13818, 1995.
52. Frank SJ, Woelsung Y, Zhao Y, Goldsmith JF, Gilliland G, Jiang J, Sakai I and **Kraft AS**: Regions of the JAK2 tyrosine kinase required for coupling to the growth hormone receptor. *J Biol Chem* 270:14776-14785, 1995.
53. Sakai I, Nabell L and **Kraft AS**: Signal transduction by a CD16/CD7/Jak2 fusion protein. *J Biol Chem* 270:18420-18427, 1995.

54. Asiedu C, Biggs J, Lilly M and **Kraft AS**: Inhibition of leukemic cell growth by the protein kinase activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. *Cancer Res* 55:3716-3720, 1995.
55. Franklin C and **Kraft AS**: Constitutively active MAP kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. *Oncogene* 11:2365-2374, 1995.
56. Adler V, Fuchs SY, Kim J, **Kraft AS**, King MP, Pelling J and Ronai Z: Jun-NH2-Terminal kinase activation mediated by uv-induced DNA lesions in melanoma and fibroblast cells. *Cell Growth & Differentiation* 6:1437-1446, 1995.
57. **Kraft AS**, Woodley S, Pettit GR, Gao F, Coll JC and Wagner F: Comparison of the antitumor activity of bryostatin 1,5 and 8. *Canc Chem Pharm* 37:271-278, 1996.
58. Biggs JR, Kudlow JE and **Kraft AS**: The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. *J Biol Chem* 271:901-906, 1996.
59. Zhang X, Zhang R, Zhao H, Cai H, Gush GA, Kerr RG, Pettit GR, and **Kraft AS**: Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. *Cancer Res* 56:802-808, 1996.
60. Bignami GS, Wagner F, Grothaus PG, Rustagi P, Davis DE and **Kraft AS**: Biological activity of 26-succinylbryostatin 1. *Biochim Biophys Acta* 1312:197-206, 1996.
61. Yi W, Kim S-O, Jiang J, Park S-H., **Kraft AS**, Waxman DJ and Frank SJ: Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of STAT5b and STAT3 by activated JAK2 kinase. *Molecular Endocrinology* 10:1425-1443, 1996.
62. Bebok Z, Abai AM, Dong JY, King SA, Kirk KL, Berta G, Hughes BW, **Kraft AS**, Burgess SW, Shaw W, Felgner PL and Sorscher EJ: Efficiency of plasmid delivery and expression after lipid-mediated gene transfer to human cells *in vitro*. *J Pharmacol Exp Ther* 279:1462-1469, 1996.
63. Zhao Y, Loyer P, Li H, Valentine V, Kidd V and **Kraft AS**: Cloning and chromosomal location of a novel member of the myotonic dystrophy family of protein kinases. *J Biol Chem* 272:10013-10020, 1997.
64. Franklin C and **Kraft AS**: Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. *J Biol Chem* 272:16917-16923, 1997.
65. Lilly M and **Kraft AS**: Enforced expression of 33kd pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. *Cancer Res* 57:5348-5355, 1997.
66. Sakai I and **Kraft AS**: The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. *J Biol Chem* 272:12350-12358, 1997.
67. Li X, Franklin CC, **Kraft AS** and Carter RH: Ligation of membrane IgM stimulates a novel c-Jun amino-terminal domain kinase activity in Daudi human B cells. *Mol Immunology* 34:409-418, 1997.
68. Asiedu C, Biggs J and **Kraft AS**: Complex regulation of CDK2 during phorbol ester-induced hematopoietic differentiation. *Blood* 90:3430-3437, 1997.
69. Matsuguchi T, Zhao Y, Lilly MB and **Kraft AS**: The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor α -subunit is essential for both GM-CSF-mediated growth and differentiation. *J Biol Chem* 272:17450-17459, 1997.
70. Turner T, Jackson WH, Pettit GR, Wells A. and **Kraft AS**: Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. *The Prostate* 34:175-181, 1998.
71. Srikanth S and **Kraft AS**: Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death *in vivo*. *Cancer Res* 58:834-839, 1998.

72. Franklin CC, Srikanth S and **Kraft AS**: Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. *Proc Nat Acad Sci* 95:3014-3019, 1998.
73. Biggs JR, Ahn NG and **Kraft AS**: Activation of the mitogen-activated protein kinase pathway in U937 leukemic cells induces phosphorylation of the amino terminus of the TATA-binding protein. *Cell Growth & Differentiation* 9:667-676, 1998.
74. Matsuguchi T, Lilly MB and **Kraft AS**: Cytoplasmic domains of the human granulocyte macrophage colony-stimulating factor receptor β chain (h β c) responsible for human GM-CSF-induced myeloid cell differentiation. *J Biol Chem* 273:19411-19418, 1998.
75. Matsuguchi T and **Kraft AS**: Regulation of myeloid cell growth by distinct effectors of Ras. *Oncogene* 17:2701-2709, 1998.
76. Hedlund TE, Schaack JB, Meech SJ, Miller GJ, **Kraft AS**, Srikanth S and Duke RC: Adenovirus-mediated expression of Fas Ligand in human prostate cancer cell lines. *Cell Death & Differentiation* 6:175-182, 1998.
77. Burgess GS, Williamson, EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, **Kraft AS**, Nakshatri H and Boswell HS: Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun n-terminal kinase. *Blood* 92:2450-60, 1998.
78. Lilly MB, Koskinen P, Cooper JJ and **Kraft AS**: The Pim-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through regulation of *bcl-2* expression. *Oncogene* 18:4022-4031, 1999.
79. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, **Kraft AS**, Dubowy RL, Smith DL, and Berstein M: A phase I trial of bryostatins in children with refractory solid tumors: a pediatric oncology group study. *Clin Cancer Res* 5:2344-8, 1999.
80. Gonzalez R, Ebbinghaus S, Henthorn T, Miller D, **Kraft AS**: Treatment of Patients with Metastatic Melanoma with Bryostatins – A Phase II Study. *Melanoma Research* 19:599-606, 1999.
81. Biggs J and **Kraft AS**: The Role of the Smad3 Protein in Phorbol Ester—Induced Promoter Expression. *J Biol Chem* 274:36987-36994, 1999.
82. Srikanth S, Franklin C, Duke R, and **Kraft AS**: Human DU145 Prostate Cancer Cells Overexpressing Mitogen-Activated Protein Kinase Phosphatase-1 are resistant to Fas ligand-induced Mitochondria Perturbations and Cellular Apoptosis. *Molecular and Cellular Biochemistry* 199:169-178, 1999.
83. Zhang W, Geiman D, Shields J, Dang D, Mahatan C, Kaestner K, Biggs J, **Kraft AS**, Yang V: The gut-enriched kruppel-like factor (Kruppel-Like Factor 4) mediates the transactivating effect of p53 on the p21^{WAF/Cip1} promoter. *J Biol Chem* 275:18391- 8, 2000.
84. Pawlowski J, Nesterov A, Scheinman R, Johnson T and **Kraft AS**: NF- κ B Activity does not modulate sensitivity of renal carcinoma cells to TNF α related apoptosis inducing ligand (TRAIL). *AntiCancer Res* 20:4243-4255, 2000.
85. Johnson T, Biggs J, Winbourn S, and **Kraft AS**: Regulation of Dual-Specificity Phosphatases M3/6 and hVH5 by Phorbol Esters: Analysis of A Delta-like Domain. *J Biol Chem* 275:31755-31772, 2000.
86. Vaishampayan U, Glode M, **Kraft AS**, Hudes G, Wright J, and Hussain M: Phase II Study of Dolastin-10 in Patients with Hormone Refractory Metastatic prostate adenocarcinoma (HRPCA). *Clin Cancer Res* 11:4205-8, 2000.
87. Lilly MB, Zemskova M, Frankel AF, Salo J, **Kraft AS**: Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. *Blood* 97:1662-1670, 2001.

88. Biggs J, Yang J, Gullberg U, Muchardt C, Yaniv M, **Kraft AS**: The human brm protein is cleaved during apoptosis. The Role of Cathepsin G. *Proc Nat Acad Sci* 98:3814-3819, 2001.
89. Nesterov A, Lu X, Johnson M, Miller G, Ivashchenko Y, **Kraft AS**: Elevated Akt activity protects the prostate cancer cell line LNCap from TRAIL-induced apoptosis. *J Biol Chem* 276:10767-10774, 2001.
90. Matsuguchi T, Musikacharoen T, Johnson T, **Kraft AS**, Yoshikai Y: A Novel MAP Kinase Phosphatase is an Important Negative Regulator of LPS-mediated JNK activation in Mouse Macrophage Cell Lines. *Mol Cell Biol* 21:6999-7009, 2001.
91. Nesterov A, Ivashchenko Y, **Kraft AS**: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Triggers Apoptosis in Normal Prostate Epithelial Cells. *Oncogene* 21:1135-1140, 2002.
92. Ionov I, Le X, Tunquist B, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly M, and **Kraft AS**: Pim-1 Protein Kinase is nuclear in Burkitt's lymphoma: Nuclear localization is necessary for its biological effects. *Anticancer Res* 23:167-178, 2003.
93. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX Thompson CB, Nesterov A, and **Kraft AS**: The proteasome inhibitor PS-341 overcomes TRAIL-resistance in Bax and caspase 9 negative or Bcl-xL overexpressing cells. *Oncogene* 22:4953-4963, 2003.
94. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, **Kraft AS**, Eltoum I, Abdulkadir S: Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. *Cancer Res.*, 23:8079-84, 2003.
95. Yan B, Zemskova M, Holder S, Chin V, **Kraft AS**, Koskinen PJ, and Lilly M: The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death. *Journal of Biological Chemistry*, 278 (46):45358-67, 2003.
96. Nesterov A, Nikrad M, Johnson T, and **Kraft AS**: Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha related apoptosis-inducing ligand-induced apoptosis *Cancer Res.* 64(11):3922-7, 2004.
97. Zhang Y, Biggs JR, and **Kraft AS**. Phorbol Ester Treatment of K562 Cells Regulates the Transcriptional Activity of AML1c Through Phosphorylation. *Journal of Biological Chemistry* 279(51) 53116-25, 2004.
98. Maki RG, **Kraft AS**, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, and Schwartz GK: A Multicenter Phase II Study of Bortezomib in Recurrent or Metastatic Sarcomas. *Cancer* 103:1431-38, 2004
99. von Mehren M, Balcerzak SP, **Kraft AS**, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT and Rogatko A. Phase II Trial of Dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. *Sarcoma* 8:107-11, 2004
100. Nikrad M, Johnson T, Puthalalath, H, Coultas, L, Adams, J and **Kraft, AS**: The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. *Mol Cancer Ther.* 4:443-9, 2005
101. Chen WW, Chan DC, Donald C, Lilly MB, and **Kraft AS**: Pim family kinases enhance tumor growth of prostate cancer cells. *Mol. Cancer Res.* 3: 443-451, 2005.
102. Biggs J, Zhang Y, Garcia M, and **Kraft AS**: Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. *Mol Cancer Res.* 3:391-401, 2005.
103. Sui M, Xiong X, **Kraft AS**, Fan W. Combination of Gemcitabine Antagonizes Antitumor Activity of Paclitaxel through Prevention of Mitotic Arrest and Apoptosis. *Cancer Biol Ther.* 8: 1015-1021, 2006

104. Biggs J, Peterson L, Zhang Y, **Kraft AS**, Zhang DE. AML1/RUNX1 phosphorylation by cyclin dependent kinases regulates the degradation of AML1/RUNX1 by the Anaphase-Promoting Complex. *Molecular Cell Biol.* 20: 7420-7429, 2006.
105. Wang S, Zhang Y, Soosairajah J, **Kraft AS**. Regulation of AML1/RUNX1 During the G2/M Transition. *Leuk. Res.* 6: 839-851, 2007.
106. Ma J, Arnold H, Lilly, MB, Sears R, **Kraft AS**. Negative regulation of PIM-1 protein kinase levels by the B56 β subunit of PP2A. *Oncogene* 26: 5143-5153, 2007.
107. Skorupa A, Beldner M, **Kraft A**, Montero A. Fatal Rhabdomyolysis as a Complication of ET-743 (Yondelis) Chemotherapy for Sarcoma. *Cancer Biol Ther.* 6 (7): 1015-1017, 2007 PMID: 17611408
108. Xiong X, Sui M, Fan W, **Kraft AS**. Cell-Cycle Dependent Antagonistic Interactions between Paclitaxel and Carboplatin in Combination Therapy. *Cancer Biol Ther.* 6 (7): 1067-1073, 2007 PMID: 17568189
109. Hayslip J, Green M, **Kraft AS**, Montero, A. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. *BMC Cancer* 7:221, 2007. PMCID: PMC2234426
110. Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I Dose Escalation Study of Vinorelbine and Topotecan Combination Chemotherapy in Patients with Recurrent Lung Cancer. *BMC* 7: 231, 2007. PMCID: PMC2241632
111. Kandasamy K, **Kraft AS**. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. *Mol Cancer Ther.* 7:1091-100, 2008. PMID: 18483298
112. Mahajan S, Dammai V, Hsu T, **Kraft AS**. Hypoxia-inducible Factor 2 α regulates the expression of TRAIL receptor DR5 in renal cancer cells. *Carcinogenesis* (9): 1734-41, 2008 PMID: 18544564
113. Song JH, Kandasamy K, **Kraft AS**. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. *J Biol Chem* 283:25003-13, 2008. PMID: 18599488
114. Xia Z, Knaak C, Beharry Z, McInnes C, **Kraft AS**, Smith CD. Synthesis and Evaluation of Novel Pim-1 and Pim-2 Inhibitors. *J Med Chem.* 2009 Jan 8;52(1):74-86. PMID 19072652
115. Maki R, D'Adamo D, Keohan M, Saulle M, Schuetze S, Undevia S, Livingston M, Cooney M, Hensley M, Mita M, Takimoto C, **Kraft A**, Elias A, Brockstein B, Blachere N, Edgar M, Schwartz L, Qin L, Antonescu C, Schwartz G. A phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *JCO* 2008 Submitted
116. Beharry Z, Zemsanova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith C, **Kraft A**. Novel Benzylidene-thiazolidine-2,4-diones Inhibit Pim Protein Kinase Activity and Induce Cell Cycle Arrest In Leukemia and Prostate Cancer Cells. *Mol Cancer Ther.* 2008 Submitted
117. Zhang F, Beharry Z, Harris T, Lilly M, Smith C, **Kraft A**. Pim 1 Protein Kinase Regulates PRAS40 Phosphorylation and mTOR Activity in FDCP1 Cells. *Cancer Biology & Therapy* 2009 Submitted

Abstracts

1. Berkow RL, Dodson RW, and **Kraft AS**: Human neutrophils (PMN) contain separate cytosolic and particulate (Part) tyrosine protein kinase (TPK) activities. FASEB 1988 Presentation.
2. William F, Cohen S and **Kraft AS**: Differentiation HL-60 Cells is associated with increases in the 35 kDa substrate of the EGF Receptor/Protein Kinase J Cell Biochem 2A:207, 1988.
3. Reeves JA, Baudoin P, Ashendel C, and **Kraft AS**: Bryostatin is less potent than phorbol esters in inducing non-adherent growth of mouse epidermal cells. Proc Amer Assoc Canc Res 28:175, 1987.
4. Lilly MB, **Kraft AS** and Rado T: Leukemia-differentiating activity (LDA) expressed by a human melanom line. Blood 70:19 194a, 1987.
5. **Kraft AS**, Baker VV and May WS: Activation of protein kinase C is not sufficient to induce differentiation of HL-60 cells. J Cell Biochem. 11a:66, 1987.
6. Berkow RL, Dodson R and **Kraft AS**: Protein kinase C does not control neutrophil activation by chemotactic peptics. Clin Res 34: 451a, 1986.
7. May WS, **Kraft AS** and Sensenbrenner LL: Transferrin receptor: Regulation by bryostatin 1SEH, 1986.
8. Berkow RL, Dodson R and **Kraft AS**: Dissociation of neutrophil (PMN) activation events by extended treatment with amiloride. Clin Res 34: 451a, 1986.
9. **Kraft AS**, Cunningham K and Berkow RL: Specific binding phorbol esters to isolated nuclei. Amer Assoc Can Res 27: 144, 1986.
10. Berkow RL, Dodson R and **Kraft AS**: Amiloride (Am) dissociates human neutrophil (N) activation events. FASEB 45: 1986.
11. **Kraft AS**, Cunningham K and Berkow RL: Phorbol esters specifically bind to isolated nuclei. Amer Assoc Can Res 27: 144, 1986.
12. **Kraft AS**, Cunningham K and Berkow RL: Characterization of a cytosolic tyrosine-phosphorylating cell line (HL-60) and polymorphonuclear leukocytes. Blood 66:130a, 1985.
13. **Kraft AS** and Berkow RL: Activation of the calcium/phospholipid-dependent protein kinase is not sufficient to induce differentiation of HL-60 cells. Blood 66: 168a, 1985.
14. Berkow RL, Dodson R and **Kraft AS**: Protein kinase C (PKC) does not control neutrophil (N) activation by chemotactic peptides. Blood 66: 76a, 1985.
15. **Kraft AS** and Berkow RL: Bryostatin, an activator of C-kinase, blocks phorbol ester induced differentiation of HL-60 cells. J Cell Biol 101: 250a, 1985.
16. Berkow RL and **Kraft AS**: Bryostatin activates human neutrophilism by binding to the phorbol receptor. Clin Res 33: 335a, 1985.
17. **Kraft AS**: Phorbol esters potentiate the activity of B-transforming growth factor. Pro Amer Assoc CA Res 26: 140, 1985.
18. **Kraft AS** and Zuckerman KS: Production of multilineage hemopoietic growth stimulating activity of a human melanoma cell line. Blood 64: 429, 1984.
19. Sando JJ, **Kraft AS**, Cooper HL and Anderson WB: Phorbol ester treated EL4 rhyon cells exhibit a marked decrease in cytosolic calcium phospholipid-dependent protein kinase activity. Proc Amer Assoc Ca Res 23: 99, 1982.
20. Anderson WB and **Kraft AS**: Effect of retinoic acid and phorbol ester treatment of embryonal carcinoma cells on calcium, phospholipid-dependent protein kinase activity. In: Teratocarcinoma Stem Cells. Cold Spring Harbor Symposium, 1982.

21. **Kraft AS** and Anderson WB: Calcium, phospholipid-dependent protein kinase activity in embryonal carcinoma cells. *J Cell Biol* 91 (2): 30, 1981.
22. Lilly M, William F, Pettit G, and **Kraft AS**: Bryostatin 1 induces differentiation and modulates growth of human myeloid leukemias. *Blood* Vol 72: 2129, 1988
23. Fields AP, Ramprasad M, **Kraft AS** and May WS: Platelet derived growth factor (PDGF) induces translocation and activation of protein kinase C (PKC) as the nuclear membrane. *Blood* Vol 72: 2129, 1988.
24. **Kraft AS**, Wagner F, and House GM: Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1. *Oncogene* Vol 5, 1243-1246, 1990.
25. Adunyah SE, Unlap T, **Kraft AS**: Okadaic Acid, A Phosphatase inhibitor, induces the macrophage-differentiation of U937 cells. *Blood* Vol 76, No. 10, Supp 1, 346, 1990.
26. Unlap T, Adunyah SE, Wagner F and **Kraft AS**: Regulation of specific DNA enhancer activity during lineage determination in U937 cells *Blood* Vol 76, No. 10 Supp 1, 489, 1991.
27. **Kraft AS**, Unlap T, Adunyah SE and Wagner F: Regulation of AP-1 enhancer activity and c-Jun RNA levels during the differentiation of U037 human leukemic cells. *J Cell Biol* 246 Suppl 15B, 1991.
28. Unlap T, Franklin CC, Wagner F, Adunyah SE and **Kraft AS**: Upstream regions of the c-Jun promoter regulates phorbol ester-induced transcription in U937 leukemic cells. *Blood* Vol 78, No 10 Supp 1, 312a, 1991.
29. Franklin CC, Sanchez V, Wagner F, Woodgett and **Kraft AS**: Phorbol ester-induced amino terminal phosphorylation of c-Jun but not Jun B regulates transcriptional activation, *J Cell Biochem* 16B 237, 1992.
30. Franklin CC, Wagner FH, McCulloch VA, Asiedu CK and **Kraft AS**: The Jun family of transcriptional activators interact directly with both the TATA binding protein (TBP) and TFIIB). 46th Annual Symposium on Fundamental Cancer Research, 1993.
31. Vaishampayan U, Glode M, Crawford D, **Kraft AS**, Hudes G, Wright J, and Hussain: Phase II Study of Dolastatin-10 in Patients with Hormone Refractory Metastatic Prostate Cancer (HRPCA) 91st Annual Meeting for the American Association for Cancer Research, 1999.
32. Helfrich B, Phistry M, Kraft A, Raben D; TNF-related apoptosis-inducing Ligand (TRAIL/APO2L) enhances ionizing radiation cytotoxicity in human cholangiocarcinoma cells *in vitro*. Submitted to ASTRO and ESTRO, 2000.
33. Wang S, Zhang Y, Biggs JR, Zhang D and Kraft AS: Phosphorylation of AML1 (RUNX1) controls transcription, nuclear localization, and is regulated during DNA damage. 47th ASH Annual Meeting
34. Kandasamy K, **Kraft AS**. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'- untranslated region. AACR Annual Meeting 2008
35. Mahajan S, Dammai V, Hsu T, **Kraft A**. Hypoxia-inducible Factor-2 α Regulates The Expression of TRAIL Receptor DR5 in Renal Cancer Cells. AACR Annual Meeting 2008
36. Song JH, Kandasamy K, **Kraft AS**. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL- induced apoptosis. AACR Annual Meeting 2008
37. Lin Y, Beharry Z, Song J, Smith C, **Kraft A**. Novel Small Molecule Pim Protein Kinase Inhibitors Induce Cell Cycle Arrest and Apoptosis in Human Leukemias: A Potential Therapeutic Approach. ASH Annual Meeting 2008.